loader2
Login Open ICICI 3-in-1 Account
Text Size
Text to Speech
Color Contrast
Pause Animations
Open ICICI 3-in-1 Account

Nifty Midcap 150 Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
GMR Airports Ltd. 16 Feb 2026 12:06 PM
Result PDF

Q3FY26 Quarterly Result Announced for GMR Airports Ltd.

Construction & Engineering company GMR Airports announced Q3FY26 results

  • Total Income: Rs 4,083 crore against Rs 2,748 crore during Q3FY25, change 49%.
  • EBITDA: Rs 1,789 crore against Rs 1,087 crore during Q3FY25, change 65%.
  • PBT: Rs 408 crore against Rs -221 crore during Q3FY25, change 285%.
  • PAT: Rs 174 crore against Rs 202 crore during Q3FY25, change -14%.

Result PDF

Result PDF

Financial Services company Crisil announced Q4CY25 results

  • Consolidated income from operations for Q4CY25 was up 18.5% to Rs 1,081.6 crore, compared with Rs 912.9 crore in Q4CY24.
  • Consolidated total income for Q4CY25, rose 17.5% to Rs 1,108.7 crore, compared with Rs 943.2 crore in Q4CY24.
  • Profit before tax for Q4CY25 was up 10.9% to Rs 326.5 crore, compared with Rs 294.5 crore in Q4CY24.
  • Profit after tax was up 7 .5% to Rs 241.5 crore, compared with Rs 224.7 crore in Q4CY24.
  • The Board of Directors has recommended a final dividend of Rs 28 per share (of Re 1 face value), taking the total dividend for the year to Rs 61 per share.

Says Amish Mehta, Managing Director & CEO, Crisil, said: "We saw strong revenue and EBITA growth compared with last year, driven by consistent financial delivery and operational resilience across our businesses. While a dynamic macroeconomic backdrop persists, we are committed to delivering sustainable growth through continuous investments in creating new products and solutions, expanding our client footprint, and developing future-ready talent. We focus on creating domain-led GenAI solutions that drive competitiveness by enhancing client experiences and insights and augmenting operational efficiencies. Notably, Crisil is marching towards its 40th year of making markets function better, driven by deep institutional intelligence and rich experience honed by economic cycles, reforms and shocks, and as a steadfast ally in the Viksit Bharat quest."

Result PDF

Pharmaceuticals company Alkem Laboratories announced Q3FY26 results

  • Total Revenue from Operations was Rs 37,368 million, with YoY growth of 10.7%.
    • India sales were Rs 24,959 million, YoY growth of 5.5%.
    • International sales were Rs 12,157 million, with YoY growth of 26.6%.
  • Earnings before Interest, Tax, Depreciation, and Amortisation (EBITDA) were Rs 8,280 million, resulting in an EBITDA margin of 22.2% vs 22.5% in Q3FY25. EBITDA grew by 9.0% YoY.
  • R&D expenses for Q3FY26 were Rs 1,390 million, or 3.7% of total revenue from operations, vs Rs 1,312 million in Q3FY25 at 3.9% of total revenue from operations.
  • Profit before tax (after exceptional item) was Rs 7,812 million, YoY growth of 6.9%.
  • Net Profit (after Non-Controlling interest) was Rs 6,360 million, YoY growth of 1.6%.
  • Exceptional item for the quarter includes the impact of Rs 528 million on a preliminary basis related to the notification by the Government of India regarding the four Labour Codes.
  • According to IQVIA (SSA) data, for Q3FY26:
    • The Company registered a growth of 9.8% YoY vs the Indian Pharmaceutical Market (IPM), which grew by 10.9%.
    • Acute segment reported growth of 8.6% vs IPM, which grew by 7.8%, 80 bps outperformance.
    • Chronic segment reported growth of 15.8% vs IP,M which grew by 15.6%, 18 bps outperformance.

Sandeep Singh, Managing Director, Alkem Laboratories, said: “This acquisition holds strategic importance as we work towards establishing a global footprint in medical devices. Occlutech is the third-largest player globally in the minimally invasive cardiac implants segment. With its significant presence in high-barrier markets, best-in-class R&D and manufacturing, and robust quality systems, Occlutech provides a strong lever for Alkem MedTech to expand into cardiovascular, along with orthopaedics. Medtech is a natural extension for Alkem. In the company years, along with Enzene Biosciences, our Biotech arm, we expect Alkem MedTech to become a meaningful growth pillar for the company.”

Vikas Gupta, CEO, Alkem, said: “In Q3, we delivered a stable performance in a dynamic operating environment, supported by strong fundamentals in our domestic business and consistent execution across our international businesses. We remain bullish on the growth opportunities in domestic as well as international business and are on track to deliver our full-year guidance. Looking ahead, the planned launch of our GLP-1 semaglutide in March 2026 is expected to be among our key growth drivers. Our focus remains on execution, strengthening our product portfolio, and building long-term competitiveness across markets.”

Result PDF

Pharmaceuticals company Ipca Laboratories announced Q3FY26 results

Consolidated Financial Highlights:

  • Consolidated Net total Income up 7% at Rs 2,412.69 crore.
  • Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 22.15% in Q3FY26 as against @ 19.87% in Q3FY25.
  • Consolidated Net Profit at Rs 326.27 crore (after exceptional items) up 31%.
  • Exports Income up 13% at Rs 770.49 crore.

Standalone Financial Highlights:

  • Standalone Net total Income up 11% at Rs 1,863.00 crore.
  • Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 26.09% in Q3FY26 as against @ 24.25% in Q3FY25.
  • Standalone Net Profit at Rs 303.45 crore (after exceptional items) up 13%.
  • Indian formulations income up 12% at Rs 984.00 crore.

Result PDF

Pharmaceuticals company Lupin announced Q3FY26 results

  • Gross Profit was Rs 52,224 million compared to Rs 38,970 million in Q3FY25, with a gross margin of 73.5%.
  • Personnel cost was 16.1% of sales at Rs 11,433 million compared to Rs 9,844 million in Q3FY25.
  • Manufacturing and other expenses were 27.3% of sales at Rs 19,366 million compared to Rs 16,959 million in Q3FY25.
  • Adjusted PBT at Rs 15,220 million at 21.4%, up 42.1% YoY from Rs 10,713 million in Q3FY25.
  • PBT (excluding exceptional items) is Rs 19,486 million at 27.4%.
  • We have provided net one-time exceptional items of Rs 4,266 million.
  • Investment in R&D for the quarter was Rs 5,352 million (7.5% of sales).

Nilesh Gupta, Managing Director, Lupin, said: “We are happy to deliver another quarter of strong growth led by our highest ever quarterly sales in the US and double-digit growth in India and all other regions. We are on track to deliver a strong close to FY26."

Result PDF

Agrochemicals company PI Industries announced Q3FY26 results

  • Total Income: Rs 13,757 million against Rs 19,008 million during Q3FY25, change -28%.
  • EBITDA: Rs 3,027 million against Rs 5,122 million during Q3FY25, change -41%.
  • EBITDA Margin: 22% for Q3FY26.
  • PAT: Rs 3,113 million against Rs 3,727 million during Q3FY25, change -16%.
  • The company saw a ~32% decline in Agchem Exports (Volume down ~ 29 %) in line with the customer delivery schedule.
  • Pharma revenue contracted by 6% YoY due to the deferment of supply schedules to Q4FY26. Pharma revenue contributes ~5% of the export revenue.
  • Overheads increase, comprising the strategic development of new businesses and the promotion of new products (6%), offset by effective cost control in existing businesses.
  • The Board has approved an interim dividend for FY25-26 of Rs 5.00 per share.

Result PDF

Auto Parts & Equipment company Endurance Technologies announced Q3FY26 results

  • Total Income: Rs 3,646 crore against Rs 2,881 crore during Q3FY25, change 27%.
  • EBITDA: Rs 514 crore against Rs 394 crore during Q3FY25, change 30%.
  • EBITDA Margin: 14.1% for Q3FY26.
  • PBT: Rs 301 crore against Rs 247 crore during Q3FY25, change 22%.
  • PAT: Rs 222 crore against Rs 184 crore during Q3FY25, change 21%.
  • PAT Margin: 6.1% for Q3FY26.

Anurang Jain, Managing Director, said: "Two-wheeler sales volumes for Indian OEMs grew 18.2% YoY in Q3FY26; while passenger vehicle volumes recorded a 19.2% YoY growth. Endurance standalone Total Income grew ahead of market at 22.2%. Market growth was on account of improved affordability following the GST rationalisation, which continues to aid demand growth even after the festive season. An average end-user has become increasingly disce(ning, with preference for safer and more premium offerings. Consequently, OEMs are expanding feature content across both ICE and electric platforms.

We are well positioned to benefit from this shift through our strong presence in safety-critical categories such as disc brake systems and ABS, and in premium products such as Inverted Front Forks and Assist and Slip Clutches. Alongside our established leadership in two-wheelers, we are focused on expanding our presence in four-wheeler programmes and non-automotive applications, and a large part of our new orders won this year are for these applications.

In Europe, new car registrations during the quarter grew at 4.6% YoY, while our revenue growth in Euro terms was at 21%. The acquisition of Stoferle, which was consummated at the start of this financial year, has not only helped us to grow our business but also to diversify our customer base and strengthen our machining capabilities. Efforts are underway to identify more such inorganic opportunities, both in India and Europe.

In our Indian operations, significant efforts are underway to cross key growth milestones in FY27. These target milestones include full utilisation of our newly commissioned Bidkin plant, start of commercial production at our new facilities at Mindewadi near Pune, Shendra, Chennai, G4S Waluj and also expansions in Sanand and ABS facilities."

Result PDF

Travel Support Services company Indian Railway Catering & Tourism Corporation announced Q3FY26 results

  • Revenue from operations: Rs 1,44,947.25 lakh against Rs 1,22,465.59 lakh during Q3FY25, change 18%.
  • PBT: Rs 52,920.32 lakh against Rs 45,655.04 lakh during Q3FY25, change 16%.
  • PAT: Rs 39,573.04 lakh against Rs 34,258.54 lakh during Q3FY25, change 16%.
  • EPS: Rs 4.93 for Q3FY26.

Result PDF

Industrial Machinery company 3M India announced Q3FY26 results

  • Revenue: Rs 1,228 crore against Rs 1,090 crore during Q3FY25, change 13%.
  • EBITDA: Rs 240 crore against Rs 171 crore during Q3FY25, change 40%.
  • PBT: Rs 189 crore against Rs 154 crore during Q3FY25, change 23%.
  • PAT: Rs -62 crore against Rs 114 crore during Q3FY25, change -154%.

Ramesh Ramadurai, Managing Director, 3M India, said: “The Company delivered 12.7% sales growth in Q3FY26 versus prior year. The Company delivered broad-based growth across all four business segments. For the quarter, Safety & Industrial sales grew by 20.1%, Healthcare 13.5%, Consumer 12.3%, and Transportation & Electronics 3.9% versus prior year. For the 9MFY26, the Company delivered sales growth of 13.6%.

During the quarter, the Company recognized a charge for additional liabilities arising from implementation of the recently announced labor codes, as an exceptional item. During the quarter, the company received a final draft of the Advance Pricing Agreement (APA) from the tax authorities. After due consideration, the Company has decided to accept this proposal, which has resulted in an additional tax expense and interest cost. The APA will help resolve long-pending tax litigation matters. Details have been provided in the Notes to the financial results.

Excluding these special causes (labor code impact, interest cost related to APA), the Company delivered PBT of Rs. 221 crores for Q3 of current year, a 43% growth over prior year, at 17.8% margins. For the nine months ending December 2025, the Company delivered PBT of Rs. 711 crores, a growth of 29.7% versus prior year, at 19.1% margins (excluding special causes noted above). The Company continues to be watchful of material cost pressures due to adverse foreign exchange movements.

Due to these special causes and the additional tax expense pertaining to APA, the Company recorded a loss of Rs. 62 crores (after tax) in the current quarter. PAT for the nine months ending Dec 2025 stood at Rs. 307 crores.

I sincerely thank the Board, shareholders, and the 3M team for their support to me during my tenure as Managing Director. I welcome Aseem Joshi as the incoming Managing Director effective April 1, 2026, and wish him and the 3M India team the very best.

Result PDF

Pharmaceuticals company Abbott India announced Q3FY26 results

  • Revenue: Rs 1,724.04 crore against Rs 1,614.28 crore during Q3FY25, change 7%.
  • PBT: Rs 508.98 crore against Rs 487.59 crore during Q3FY25, change 4%.
  • PAT: Rs 375.96 crore against Rs 360.78 crore during Q3FY25, change 4%.
  • EPS: Rs 176.92 for Q3FY26.

Result PDF

Trending News

Nestle India adds 20,500 tonnes of Maggi capacity at Sanand facility

Nestle India has announced addition of 20,500 tonnes/annum of Maggi capacity at Sanand facility. 

Published on 02-Apr-2026 09:19

Power Grid wins transmission project for 2.7 GW of renewable energy capacity at Tumkur-II, Karnataka

Power Grid Corporation of India Limited (POWERGRID) has been declared the successful bidder under Tariff-Based Competitive Bidding (TBCB) for a transmission project aimed at integrating 2.7 GW of additional renewable energy capacity at Tumkur-II, Karnataka. 

Published on 02-Apr-2026 09:18

Tata Power resumes operations at 4,150 MW Mundra thermal power plant

Tata Power Company Limited has resumed operations at its 4,150 MW Mundra thermal power plant in Gujarat from April 1, 2026, after a nine-month shutdown. 

Published on 02-Apr-2026 09:17

Indian Bank's gross advances grow 13.6% YoY to ₹6,680 lakh crore

Indian Bank reported steady business growth in Q4FY26 (provisional), with gross advances rising to ₹6.68 lakh crore, up 13.6% YoY (4.5% QoQ). 

Published on 02-Apr-2026 09:16

South Indian Bank's gross advances grow 15.7% YoY to ₹101,295 crore

South Indian Bank reported steady business growth in Q4FY26 (provisional), with gross advances rising to ₹1,01,295 crore, up 15.7% YoY (4.7% QoQ). 

Published on 02-Apr-2026 09:15

Karnataka Bank's gross advances grow 6.9% YoY to ₹83,336.9 crore

Karnataka Bank reported healthy sequential business growth in Q4FY26 (provisional), with gross advances rising to ₹83,336.9 crore, up 6.9% YoY (7.8% QoQ). 

Published on 02-Apr-2026 09:14

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app